



NDA 209196

TENTATIVE APPROVAL

Sanofi-Aventis U.S. LLC
Attention: Nilda Ramos
Associate Director
55 Corporate Drive
Bridgewater, NJ 00807

Dear Ms. Ramos:

Please refer to your New Drug Application (NDA) dated and received November 1, 2016, and your amendments, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for Admelog (insulin lispro injection) U-100.

This NDA provides for the use of Admelog (insulin lispro injection) U-100 for improving glycemic control in adults and children with diabetes mellitus.

We have completed our review of this application, as amended. It is tentatively approved under 21 CFR 314.105 for use as recommended in the agreed-upon enclosed labeling (text for the prescribing information, text for the patient package insert, instructions for use, carton and immediate container labels). This determination is based upon information available to the Agency at this time, [i.e., information in your application and the status of current good manufacturing practices (cGMPs) of the facilities used in the manufacture and testing of the drug product]. This determination is subject to change on the basis of any new information that may come to our attention.

The listed drug upon which your application relies is subject to a period of patent protection, and therefore final approval of your application under section 505(c)(3) of the Act [21 U.S.C. 355(c)(3)] may not be made effective until the period has expired.

Your application contains certifications to each of the patents under section 505(b)(2)(A)(iv) of the Act stating that the patents are invalid, unenforceable, or will not be infringed by your manufacture, use, or sale of, this drug product under this application ("Paragraph IV certifications").

Section 505(c)(3)(C) of the Act provides that approval of a new drug application submitted pursuant to section 505(b)(2) of the Act shall be made effective immediately, unless an action is brought for infringement of one or more of the patents that were the subject of the paragraph IV certifications. This action must be taken prior to the expiration of forty-five days from the date

the notice provided under section 505(b)(3) is received by the patent owner/approved application holder. You notified us that you complied with the requirements of section 505(b)(3) of the Act. However, because the 45-day period described in section 505(c)(3)(C) of the Act has not yet expired, final approval cannot be granted.

To obtain final approval of this application, submit an amendment two or six months prior to the: 1.) expiration of the patent or 2.) date you believe that your NDA will be eligible for final approval, as appropriate. In your cover letter, clearly identify your amendment as **“REQUEST FOR FINAL APPROVAL”**. This amendment should provide the legal/regulatory basis for your request for final approval and should include a copy of any relevant court order or judgment settlement, or licensing agreement, as appropriate. In addition to a safety update, the amendment should also identify changes, if any, in the conditions under which your product was tentatively approved, i.e., updated labeling; chemistry, manufacturing, and controls data; and risk evaluation and mitigation strategy (REMS). If there are no changes, clearly state so in your cover letter. Any changes require our review before final approval and the goal date for our review will be set accordingly.

Until we issue a final approval letter, this NDA is not deemed approved.

Please note that this drug product may not be marketed in the United States without final agency approval under Section 505 of the Act. The introduction or delivery for introduction into interstate commerce of this drug product before the final approval date is prohibited under Section 501 of the Act and 21 U.S.C. 331(d).

ADDITIONAL AGREEMENTS

If your application is ultimately approved, we remind you of your agreement submitted on June 2, 2017, stating the following:

Batch release tests of the minimum dose (1 U) are currently performed manually. After the initial launch phase of the product,

(b) (4)

(b) (4)

(b) (4)

The Agency will be provided with updated dossier documents listing the new specification. Appropriate documentation will be submitted to justify the change and to show that choosing another test point in the low dose range does not have an influence on the quality of the finished product.

If you have any questions, call Callie Cappel-Lynch, Regulatory Project Manager, at (301) 796-8436.

Sincerely,

{See appended electronic signature page}

Curtis J. Rosebraugh, M.D., M.P.H.
Director
Office of Drug Evaluation II
Office of New Drugs
Center for Drug Evaluation and Research

ENCLOSURES:

Prescribing Information
Patient Package Insert
Vial Instructions for Use
Solostar Instructions for Use
Carton and Container Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

CURTIS J ROSEBRAUGH
09/01/2017